Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pfizer tests RSV vaccine aimed at older adults

NCT ID NCT07819097

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing an RSV vaccine in healthy adults aged 60 and older to see how safe it is and how well it triggers an immune response. The trial enrolls about 600 people in China and the United States. In China, participants receive either the vaccine or a placebo; in the United States, everyone receives the vaccine. Over roughly six months, researchers track injection-site reactions, body-wide symptoms, medical problems, and antibody levels in blood tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an RSV prefusion F subunit vaccine
What this could lead to
If it works, this vaccine could help protect older adults from respiratory syncytial virus, a common cause of serious lung infections in this age group.
What could go wrong
The trial may show the vaccine does not produce a strong enough immune response, or it may cause side effects that limit its use. Results in healthy older adults may not apply to people with serious health conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria * Participants 60 years of age or older at enrolment. * Healthy participants, or participants with stable long-term medical conditions, if the investigator decides they can take part. * Adults who can walk and live in the community or in assisted-living/long-term care settings with minimal help. * Participants who can give signed informed consent and follow study visits and procedures, including the 7-day electronic diary and blood tests. Key Exclusion Criteria * Confirmed RSV infection 180 days or less before study vaccination. * Any past history of Guillain-Barré syndrome. * Severe reaction to a vaccine or severe allergy to a study vaccine component or related vaccine. * Serious or unstable medical condition that the investigator believes makes the study unsafe. * Immunocompromised status, based on medical history and/or examination. * Previous receipt of any licensed or investigational RSV vaccine or RSV preventive monoclonal antibody, or planned receipt during the study. Please refer to the study contact for further eligibility details Contacts/Locations Central Contact Person: Pfizer CT.gov Call Center Telephone: 1-800-718-1021 Email: ClinicalTrials.gov\[email protected]

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult Healthy participants

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Research Consulting, LLC

    Milford, Connecticut, 06460, United States

  • Clinical Research Partners, LLC

    Richmond, Virginia, 23226, United States

  • DM Clinical Research - Philadelphia

    Philadelphia, Pennsylvania, 19107, United States

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • J. Lewis Research, Inc. / Foothill Family Clinic Draper

    Draper, Utah, 84020, United States

  • Remington-Davis, Inc

    Columbus, Ohio, 43215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.